Celcuity (CELC) Competitors $39.91 +0.74 (+1.89%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$40.40 +0.49 (+1.23%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELC vs. ADUS, PGNY, VCYT, PACS, LFST, ARDT, NHC, GRAL, TDOC, and VRDNShould you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Addus HomeCare (ADUS), Progyny (PGNY), Veracyte (VCYT), PACS Group (PACS), LifeStance Health Group (LFST), Ardent Health (ARDT), National HealthCare (NHC), GRAIL (GRAL), Teladoc Health (TDOC), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry. Celcuity vs. Its Competitors Addus HomeCare Progyny Veracyte PACS Group LifeStance Health Group Ardent Health National HealthCare GRAIL Teladoc Health Viridian Therapeutics Addus HomeCare (NASDAQ:ADUS) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends. Do institutionals & insiders believe in ADUS or CELC? 95.4% of Addus HomeCare shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 4.6% of Addus HomeCare shares are owned by insiders. Comparatively, 15.8% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, ADUS or CELC? Addus HomeCare has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Which has stronger earnings & valuation, ADUS or CELC? Addus HomeCare has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddus HomeCare$1.15B1.67$73.60M$4.4323.69CelcuityN/AN/A-$111.78M-$3.03-13.17 Do analysts rate ADUS or CELC? Addus HomeCare currently has a consensus target price of $142.57, indicating a potential upside of 35.83%. Celcuity has a consensus target price of $39.20, indicating a potential downside of 1.78%. Given Addus HomeCare's stronger consensus rating and higher probable upside, equities analysts clearly believe Addus HomeCare is more favorable than Celcuity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addus HomeCare 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Celcuity 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ADUS or CELC more profitable? Addus HomeCare has a net margin of 6.52% compared to Celcuity's net margin of 0.00%. Addus HomeCare's return on equity of 9.23% beat Celcuity's return on equity.Company Net Margins Return on Equity Return on Assets Addus HomeCare6.52% 9.23% 6.96% Celcuity N/A -96.21%-49.44% Does the media prefer ADUS or CELC? In the previous week, Celcuity had 29 more articles in the media than Addus HomeCare. MarketBeat recorded 37 mentions for Celcuity and 8 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 1.46 beat Celcuity's score of 0.15 indicating that Addus HomeCare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addus HomeCare 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 9 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral SummaryAddus HomeCare beats Celcuity on 14 of the 16 factors compared between the two stocks. Get Celcuity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELC vs. The Competition Export to ExcelMetricCelcuityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.52B$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-13.1717.6228.6723.80Price / SalesN/A179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book12.838.508.275.55Net Income-$111.78M-$55.06M$3.24B$259.03M7 Day Performance189.83%-3.98%-3.69%-4.59%1 Month Performance206.06%9.59%4.33%4.46%1 Year Performance130.96%6.72%25.95%18.03% Celcuity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCCelcuity0.8625 of 5 stars$39.91+1.9%$39.20-1.8%+122.5%$1.52BN/A-13.1740Insider TradeAnalyst RevisionADUSAddus HomeCare4.9388 of 5 stars$109.11-0.3%$142.57+30.7%-13.9%$2.01B$1.15B24.6349,703Positive NewsUpcoming EarningsPGNYProgyny2.0349 of 5 stars$23.20+0.4%$24.82+7.0%-17.0%$1.98B$1.17B40.70310Positive NewsUpcoming EarningsVCYTVeracyte2.8967 of 5 stars$25.02-0.9%$40.90+63.5%+3.0%$1.98B$445.76M61.03790Positive NewsUpcoming EarningsHigh Trading VolumePACSPACS Group3.0969 of 5 stars$11.83+1.2%$34.29+189.8%-70.3%$1.78B$3.56B0.0032,433News CoveragePositive NewsLFSTLifeStance Health Group3.1863 of 5 stars$4.17+0.7%$8.42+101.8%-32.4%$1.61B$1.25B-41.7010,218News CoverageUpcoming EarningsARDTArdent Health3.6115 of 5 stars$10.67-3.5%$20.30+90.3%-43.2%$1.58B$5.97B6.5524,900Upcoming EarningsNHCNational HealthCareN/A$95.82-0.6%N/A-29.0%$1.48B$1.37B12.0112,400GRALGRAIL1.2123 of 5 stars$38.27-5.0%$31.50-17.7%+97.1%$1.45B$125.60M-0.631,360TDOCTeladoc Health3.4672 of 5 stars$8.18-0.2%$9.67+18.2%-19.2%$1.44B$2.55B-1.385,500News CoverageEarnings ReportAnalyst RevisionVRDNViridian Therapeutics1.0696 of 5 stars$17.26-0.1%$37.00+114.4%+6.9%$1.41B$300K-4.4850News CoverageShort Interest ↑ Related Companies and Tools Related Companies Addus HomeCare Competitors Progyny Competitors Veracyte Competitors PACS Group Competitors LifeStance Health Group Competitors Ardent Health Competitors National HealthCare Competitors GRAIL Competitors Teladoc Health Competitors Viridian Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CELC Stock Alerts